Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Using mRNa to target tumours

Eli Lilly recently announced it is investing $1.8bn in a project with CureVac to develop mRNA cancer vaccines. While their work is still at an early stage, research suggests that mRNa could guide immune attacks on tumours, revolutionising cancer treatment.

Go Top